A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model
- PMID: 18838063
- PMCID: PMC2643041
- DOI: 10.1016/j.brainres.2008.09.047
A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model
Abstract
This study was initiated due to an NIH "Facilities of Research--Spinal Cord Injury" contract to support independent replication of published studies that could be considered for a clinical trial in time. Minocycline has been shown to have neuroprotective effects in models of central nervous system injury, including in a contusive spinal cord injury (SCI) model at the thoracic level. Beneficial effects of minocycline treatment included a significant improvement in locomotor behavior and reduced histopathological changes [Lee, S.M., Yune, T.Y., Kim, S.J., Park, D.O.W., Lee, Y.K., Kim, Y.C., Oh, Y.J., Markelonis, G.J., Oh, T.H., 2003. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 20, 1017-1027.] To verify these important observations, we repeated this study in our laboratory. The NYU (MASCIS) Impactor was used to produce a moderate cord lesion at the vertebral level T9-T10 (height 12.5 mm, weight 10 g), (n=45), followed by administration of minocycline, 90 mg/kg (group 1: minocycline IP, n=15; group 2: minocycline IV, n=15; group 3: vehicle IP, n=8; group 4: vehicle IV, n=7) immediately after surgery and followed by two more doses of 45 mg/kg/IP at 12 h and 24 h. Open field locomotion (BBB) and subscores were examined up to 6 weeks after SCI and cords were processed for quantitative histopathological analysis. Administration of minocycline after SCI did not lead to significant behavioral or histopathological improvement. Although positive effects with minocycline have been reported in several animal models of injury with different drug administration schemes, the use of minocycline following contusive SCI requires further investigation before clinical trials are implemented.
Figures





Similar articles
-
A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury.Exp Neurol. 2008 Sep;213(1):129-36. doi: 10.1016/j.expneurol.2008.05.018. Epub 2008 Jul 14. Exp Neurol. 2008. PMID: 18625498 Free PMC article.
-
Minocycline treatment inhibits lipid peroxidation, preserves spinal cord ultrastructure, and improves functional outcome after traumatic spinal cord injury in the rat.Spine (Phila Pa 1976). 2013 Jul 1;38(15):1253-9. doi: 10.1097/BRS.0b013e3182895587. Spine (Phila Pa 1976). 2013. PMID: 23370685
-
Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat.J Neurotrauma. 2003 Oct;20(10):1017-27. doi: 10.1089/089771503770195867. J Neurotrauma. 2003. PMID: 14588118
-
Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review).Mol Med Rep. 2021 Jun;23(6):417. doi: 10.3892/mmr.2021.12056. Epub 2021 Apr 13. Mol Med Rep. 2021. PMID: 33846780 Free PMC article. Review.
-
Erythropoietin in spinal cord injury.Eur Spine J. 2009 Mar;18(3):314-23. doi: 10.1007/s00586-008-0829-0. Epub 2008 Nov 22. Eur Spine J. 2009. PMID: 19030901 Free PMC article. Review.
Cited by
-
Derivation of multivariate syndromic outcome metrics for consistent testing across multiple models of cervical spinal cord injury in rats.PLoS One. 2013;8(3):e59712. doi: 10.1371/journal.pone.0059712. Epub 2013 Mar 27. PLoS One. 2013. PMID: 23544088 Free PMC article.
-
Will stem cell therapies be safe and effective for treating spinal cord injuries?Br Med Bull. 2011;98:127-42. doi: 10.1093/bmb/ldr013. Epub 2011 May 17. Br Med Bull. 2011. PMID: 21586446 Free PMC article. Review.
-
Experimental spinal cord injury and behavioral tests in laboratory rats.Heliyon. 2019 Mar 8;5(3):e01324. doi: 10.1016/j.heliyon.2019.e01324. eCollection 2019 Mar. Heliyon. 2019. PMID: 30906898 Free PMC article. Review.
-
Beyond the lesion site: minocycline augments inflammation and anxiety-like behavior following SCI in rats through action on the gut microbiota.J Neuroinflammation. 2021 Jun 26;18(1):144. doi: 10.1186/s12974-021-02123-0. J Neuroinflammation. 2021. PMID: 34174901 Free PMC article.
-
Translational spinal cord injury research: preclinical guidelines and challenges.Handb Clin Neurol. 2012;109:411-33. doi: 10.1016/B978-0-444-52137-8.00026-7. Handb Clin Neurol. 2012. PMID: 23098728 Free PMC article. Review.
References
-
- Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, Holford TR, Hsu CY, Noble LJ, Nockels R, Perot PL, Salzman SK, Young W. MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. J Neurotrauma. 1996;13:343–359. - PubMed
-
- Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6:797–801. - PubMed
-
- Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci. 2004;19:3266–3276. - PubMed
-
- Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–397. - PubMed
-
- Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, Hess DC. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol. 2004;186:248–251. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials